Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities

被引：0

作者：

Danilov, Alexey ^{[1
]}

Lewis, Lionel ^{[2
]}

Brown, Jennifer ^{[3
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Dartmouth Coll, Hanover, NH USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：10 / 10

页数：1

共 50 条

[1] A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities
Danilov, Alexey V.
Lewis, Lionel D.
Lansigan, Frederick
Roudaia, Liya
Findley, Darcie L.
Jones, Susan Y.
Highhouse, Brian
Beaulieu, Bernard B.
Brown, Jennifer R.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (05) : 820 - 823
[2] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study
Cramer, P.
Fraser, G.
Chanan-Khan, A.
Demirkan, F.
Silva, Santucci R.
Pylypenko, H.
Grosicki, S.
Janssens, A.
Pristupa, A.
Mayer, J.
Dilhuydy, M. -S
Loscertales, J.
Goy, A.
Avigdor, A.
Rule, S.
Phelps, C.
Mahler, M.
Salman, M.
Howes, A.
Balasubramanian, S.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 34 - 35
[3] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
Fraser, Graeme
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Goy, Andre
Avigdor, Abraham
Rule, Simon
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Howes, Angela J.
Balasubramanian, Sriram
Chanan-Khan, Asher Alban Akmal
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
Fischer, Kirsten
Stilgenbauer, Stephan
Schweighofer, Carmen D.
Busch, Raymonde
Renschler, Jasmin
Kiehl, Michael
Balleisen, Leopold
Eckart, Michael J.
Fink, Anna-Maria
Kilp, Julia
Ritgen, Matthias
Boettcher, Sebastian
Kneba, Michael
Doehner, Hartmut
Eichhorst, Barbara F.
Hallek, Michael
Wendtner, Clemens-Martin
BLOOD, 2008, 112 (11) : 128 - 128
[5] Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).
Fischer, Kirsien
Stilgenbauer, Stephan
Schweighofer, Carmen D.
Renschler, Jasmin
Busch, Raymonde
Kiehl, Michael
Balleisen, Leopold
Eckart, Michael
Fink, Anna M.
Boettcher, Sebastian
Ritgen, Matthias
Kneba, Michael
Staib, Peter
Doehner, Hartmut
Eichhorst, Barbara F.
Hallek, Michael
BLOOD, 2007, 110 (11) : 913A - 914A
[6] Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Barrientos, Jacqueline C.
Coutre, Steven E.
de Vos, Sven
Wagner-Johnston, Nina D.
Flinn, Ian W.
Sharman, Jeff P.
Schreeder, Marshall T.
Boyd, Thomas E.
Rai, Kanti R.
Leonard, John P.
Kim, Yeonhee
Viggiano, Anthony
Jahn, Thomas M.
Furman, Richard R.
BLOOD, 2014, 124 (21)
[7] Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study
Hallek, Michael
Fraser, Graeme
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Mayer, Jiri
Dilhuydy, Marie Sarah
Loscertales, Javier
Bartlett, Nancy
Avigdor, Abraham
Rule, Simon
Sun, Steven
Mahler, Michelle
Phelps, Charles
Salman, Mariya
Howes, Angela
Chanan-Khan, Asher
LEUKEMIA & LYMPHOMA, 2017, 58 : 192 - 194
[8] Zanubrutinib vs. bendamustine plus rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA Study
Brown, Jennifer
Munir, Talha
Shadman, Mazyar
Robak, Tadeusz
Kahl, Brad S.
Ghia, Paolo
Giannopoulos, Krzysztof
Simkovic, Martin
Osterborg, Anders
Laurenti, Luca
Walker, Patricia
Opat, Stephen
Ciepluch, Hanna
Greil, Richard
Hanna, Merit
Tani, Monica
Trneny, Marek
Brander, Danielle
Flinn, Ian
Grosicki, Sebastian
Verner, Emma
Tedeschi, Alessandra
De Guibert, Sophie
Tumyan, Gayane
Laribi, Kamel
Garcia-Marco, Jose A.
Li, Jianyong
Tian, Tian
Ramakrishnan, Vanitha
Liu, Yu
Szeto, Andy
Paik, Jason
Cohen, Aileen
Tam, Constantine S.
Jurczak, Wojciech
LEUKEMIA & LYMPHOMA, 2023, 64 : S66 - S67
[9] Bendamustine with rituximab (BR) is safe treatment option with high response rate for chronic lymphocytic leukemia in elderly patients with comorbidities
Obrtlikova, Petra
Spacek, Martin
Doubek, Michael
Hadrabova, Marketa
Panovska, Anna
Svackova, Katerina
Trneny, Marek
LEUKEMIA & LYMPHOMA, 2015, 56 : 151 - 153
[10] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Badoux, Xavier C.
Keating, Michael J.
O'Brien, Susan
Wierda, William G.
Faderl, Stefan
Estrov, Zeev
Pasia, Manolo
Lerner, Susan
Sargent, Rachel L.
Kantarjian, Hagop M.
Ferrajoli, Alessandra
BLOOD, 2011, 118 (21) : 448 - 448

← 1 2 3 4 5 →